Titlebook: Osteosarcoma; Takafumi Ueda,Akira Kawai Book 2016 Springer Japan 2016 doxorubicin.ifosfamide.limb-salvage surgery.methotrexate.neoadjuvant

Annotate

Biological Reconstruction for Extremity Osteosarcoma: Long-Term Results and Current Concept of Intraction..Purpose: The long-term results of intraoperative extracorporeal irradiated bone graft (IORBG) for malignant bone tumors are analyzed to know the long-term durability of this method..Method: Seventy-two bone tumor patients treated with IORBG for the last 25 years were reviewed. The oncological

称赞

Biological Reconstruction for Extremity Osteosarcoma: Pasteurized Autogenous Bone Graftne tumors. Using this method, bone containing tumor cells is heat-treated at 60 °C for 30 min to kill the tumor and then transplanted into the same patient at the same location. This approach has distinct advantages for initial strength, anatomical fitting to the defect of the affected bone, no dise

十字架

Basic Research for Osteosarcoma Lung Metastasis (LM8)loying this model, we reported several popular candidate molecules as targets for OS lung metastasis, including MMP, motility, VEGF, etc. I also discuss new targets, tissue stiffness, and Twist-1 as future candidates against OS metastasis.

障碍物

osteosarcoma over the past three decades.Presents a multidiThis book reviews the brilliant progress made in the past three decades in clinical outcomes for osteosarcoma patients treated with a multidisciplinary approach, including limb-salvage surgery combined with neoadjuvant multidrug chemotherap

离开真充足

Biological Reconstruction for Extremity Osteosarcoma: Pasteurized Autogenous Bone Graftms since 1989. However, this method has been associated with pseudarthrosis in the short to middle term and bone resorption in the long term. Here we show its actual application and the results, with special focus on failure and long-term survival. Finally, we present an optimal indication for this method and clinical tips to reduce its failure.

adumbrate

BROTH

Genetics of Osteosarcomaachineries to drive OS cells. However, it seems that the additional genetic alterations may endow OS cells with phenotypic heterogeneity and also tools to protect them from the molecular target therapy, which should be considered for the development of new therapeutic modalities.

收到

certitude

Neoadjuvant Chemotherapy Developed in JapanJapan, and the study found the possibility to rescue poor responders. Such strategies, however, have not been verified by RCT yet. Now additional effects of ifosfamide (IFO) to postoperative chemotherapy for poor responders after preoperative chemotherapy and surgery are just tested by two RCTs.

战胜